Saito K, Warrier T, Somersan-Karakaya S, et al. Rifamycin action on RNA polymerase in antibiotic tolerant Mycobacterium tuberculosis results in differentially detectable populations. Proc Natl Acad Sci USA. 2017;114(24):E4832¬–E4840.
Warrier T, Kapilashrami K, Argyrou A, et al. N-methylation of a bactericidal compound as a resistance mechanism in Mycobacterium tuberculosis. Proc Natl Acad Sci USA. 2016;113(31):E4523–E4530.
Warrier T, Martinez-Hoyos M, Marin-Amieva M, et al. Identification of novel anti-mycobacterial compounds by screening a pharmaceutical small-molecule library against nonreplicating Mycobacterium tuberculosis. ACS Infect Dis. 2015;1(12):580–585.
Thulasi Warrier, Ph.D.
Thulasi Warrier is a research scientist I working in the Infectious Disease and Microbiome Program of the Broad Institute of MIT and Harvard under the direction of Deborah Hung. Warrier’s research focuses on antibacterial discovery targeting drug-resistant gram-negative pathogens.
Warrier joined the Broad Institute in January 2018 from Weill Cornell Medical College, where she was an instructor in microbiology and immunology following completion of her postdoctoral research under Carl F. Nathan. Her doctoral research was undertaken at the Max Planck Institute for Infection Biology in Berlin under the supervision of Stefan H.E. Kauffmann; she was awarded her Ph.D. in microbiology from Humboldt University of Berlin. She previously served a one-year junior research fellowship at the National Centre for Biological Sciences in Bengaluru, India.
In addition to her doctoral degree, Warrier holds a master’s degree in biological sciences from Birla Institute of Technology and Science, Jhunjhunu, Rajasthan, India.